培美曲塞化疗对非小细胞肺癌患者血清肿瘤标志物及细胞免疫功能的影响
| 作者: |
1尹彦,
2韩涛,
1李宏芹
1 首都医科大学附属北京友谊医院平谷医院胸外科，北京 101200 2 首都医科大学附属北京友谊医院平谷医院神经内科，北京 101200 |
| 通讯: |
尹彦
Email: movie3012@126.com |
| DOI: | 10.3978/j.issn.2095-6959.2021.07.003 |
| 基金: | 北京平谷区卫计委计划项目(pgwjw2018-12)。 |
摘要
目的：探讨培美曲塞化疗对非小细胞肺癌患者血清肿瘤标志物及细胞免疫功能的影响。方法：选取110例非小细胞肺癌患者并随机分为两组，各包括55例患者，对照组接受吉西他滨联合顺铂化疗，观察组接受培美曲塞联合顺铂化疗，比较两组化疗前后癌胚抗原(carcinoembryonic antigen，CEA)、糖链抗原125(carbohydrate antigen 125，CA-125)以及细胞角蛋白19片断(cytokeratin-19-fragment，CYFRA21-1)的变化，以及T淋巴细胞亚群水平(CD3+、CD4+、CD8+及CD4+/CD8+)水平的变化。结果：化疗后两组血清CEA、CA-125和CYFRA21-1水平均明显降低，且观察组化疗后明显低于对照组，差异均有统计学意义(P<0.05)；化疗后两组CD3+、CD4+及CD4+/CD8+明显升高，且观察组化疗后明显高于对照组，差异均有统计学意义(P<0.05)；两组化疗前后CD8+无明显变化(P>0.05)。结论：非小细胞肺癌患者采用培美曲塞化疗可有效降低血清肿瘤标志物水平及保护免疫功能。
关键词：
非小细胞肺癌；化疗；培美曲塞；肿瘤标志物；免疫功能
Effect of pemetrexed chemotherapy on serum tumor markers and cellular immune function in patients with non-small cell lung cancer
CorrespondingAuthor: YIN Yan Email: movie3012@126.com
DOI: 10.3978/j.issn.2095-6959.2021.07.003
Foundation: This work was supported by the Planning Project of Beijing Pinggu District Health and Family Planning Commission, China (pgwjw2018-12).
Abstract
Objective: To investigate the effect of pemetrexed chemotherapy on serum tumor markers and cellular immune function in patients with non-small cell lung cancer. Methods: A total of 110 patients with NSCLC were randomly divided into two groups. The control group received gemcitabine combined with cisplatin, while the observation group received pemetrexed combined with cisplatin chemotherapy. The changes of CEA, CA-125 and CYFRA21-1were compared between the two groups before and after chemotherapy, and the changes of T lymphocyte subsets (CD3+, CD4+, CD8+ and CD4+/CD8+) were also observed. Results: After chemotherapy, the serum levels of CEA, CA-125 and CYFRA21-1 in both groups were significantly decreased, and the observation group was significantly lower than the control group (P<0.05). After chemotherapy, the levels of CD3+, CD4+, and CD4+/CD8+ in both groups were significantly higher, the observation group was significantly higher than the control group (P<0.05). There was of no significant change of CD8+ before and after chemotherapy in both groups (P>0.05). Conclusion: Pemetrexed chemotherapy can effectively reduce the level of serum tumor markers and protect the immune function of patients with NSCLC.
Keywords：
non-small cell lung cancer; chemotherapy; pemetrexed; tumor markers; immune function